Table 5.
Univariate analysis of the baseline and follow-up variables according to the early outcome
| Characteristics | mRS scores ≤2 | mRS scores >2 | p | |
|---|---|---|---|---|
| Baseline | Age (years) | 57.7±12.2 | 58.0±10.5 | 0.918 |
|
| ||||
| Male sex | 78.3% (18/23) | 78.3% (18/23) | 1.000 | |
|
| ||||
| Risk factors | ||||
| Atrial fibrillation | 21.7% (5/23) | 8.7% (2/23) | 0.414 | |
| TIA before stroke | 8.7% (2/23) | 13.0% (3/23) | 1.000 | |
| Hypertension | 52.2% (12/23) | 43.5% (10/23) | 0.555 | |
| Diabetes | 8.7% (2/23) | 4.4% (1/23) | 1.000 | |
| Hyperlipidemia | 17.4% (4/23) | 8.7% (2/23) | 0.665 | |
|
| ||||
| Onset-to-MRI time (min) | 224.7±94.9 | 281.6±90.5 | 0.043 | |
|
| ||||
| NIHSS | 4 (2, 11) | 6 (4, 10) | 0.171 | |
|
| ||||
| Volume 1 (mL) | 7.5 (2.7, 19.5) | 5.1 (1.4, 38.9) | 0.965 | |
|
| ||||
| ICA/MCA TIMI 0–1 | 78.3% (18/23) | 91.3% (21/23) | 0.414 | |
|
| ||||
| Extensive PVS | 56.5% (13/23) | 69.6% (16/23) | 0.359 | |
|
| ||||
| Cases with both PCV and PMV | 56.5% (13/23) | 78.3% (18/23) | 0.116 | |
|
| ||||
| SVS positive | 56.5% (13/23) | 60.9% (14/23) | 0.765 | |
|
| ||||
| SVS length (mm) | 14.4±7.1 | 15.3±6.4 | 0.831 | |
|
| ||||
| Reperfusion therapy | 56.5% (13/23) | 43.5% (10/23) | 0.376 | |
|
| ||||
| 7-day follow-up | Volume 2 (mL) | 11.9 (4.8, 32.2) | 62.2 (31.6, 107.2) | <0.001 |
|
| ||||
| Infarct growth (mL) | 2.6 (−0.5, 15.0) | 37.1 (19.6, 86.6) | <0.001 | |
|
| ||||
| HT (PH1+PH2) | 13.6% (3/22) | 30.4% (7/23) | 0.284 | |
|
| ||||
| ICA/MCA TIMI 2–3 | 87.0% (20/23) | 47.8% (11/23) | 0.005 | |
Data are presented as mean±SD, median (interquartile range), or percentage (number/total).
mRS, modified Rankin Scale; TIA, transient ischemic attack; MRI, magnetic resonance imaging; NIHSS, National Institutes of Health Stroke Scale; ICA, internal carotid artery; MCA, middle cerebral artery; TIMI, thrombolysis in myocardial infarction; PVS, prominent vessel sign; PCV, prominent cortical veins; PMV, prominent medullary veins; SVS, susceptibility vessel sign; HT, hemorrhagic transformation; PH1, parenchymal hematoma type 1; PH2, parenchymal hematoma type 2.